CGTX earnings analysis
What we found in CGTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Cognition Therapeutics reported Q4 2026 financial results with a narrower loss compared to the previous year, despite no revenue generation. The net loss for the quarter was $4.6 million, improving from $8.5 million in Q4 2025, showing operational efficiencies. Management highlighted ongoing clinical trials and an upcoming FDA meeting as pivotal for future growth.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Reduced Net Loss Compared to Last Year
- The net loss for Q4 2026 was $4.6 million, significantly down from $8.5 million in Q4 2025.
- Improved EPS
- The diluted EPS improved from -$0.14 in Q4 2025 to -$0.05 in Q4 2026.
- Operating Expenses Decrease
- Total operating expenses in Q4 2026 were $8.8 million, down from $13.8 million in Q4 2025.
- Cash Reserves Maintained
- Cognition Therapeutics had $31.2 million in cash, cash equivalents, and restricted cash as of March 31, 2026.
- Grant Income Supports Research
- Received $4.0 million in grant income in Q4 2026, although this was down from $5.1 million in Q4 2025.
- Upcoming FDA Meeting
- Management anticipates a meeting with the FDA in May 2026 to discuss regulatory plans for zervimesine.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Net Losses
- Despite improvements, the company continues to post net losses, with a reported loss of $4.6 million in Q4 2026.
- Reliance on Grant Funding
- Continued reliance on grants, which may not be assured or forthcoming, impacting long-term sustainability.
- FDA Regulatory Risks
- Future success hinges on FDA approval processes, especially for new trials related to zervimesine.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.01
What they said about what is next.
No specific numeric guidance provided; outlook discussed in broader context.
The filing reads better than the one before it.
What came before.
- 10-K · March 26, 2026
- Cognition Therapeutics is a clinical-stage biotech focused on developing zervimesine (CT1812), an oral small molecule for Alzheimer’s disease and dementia with Lewy bodies (DLB). The company has advanced multiple Phase…
- 10-Q · November 6, 2025
- Cognition Therapeutics reported a materially smaller GAAP net loss in Q3 2025 of $4,930 (EPS -$0.06) versus a loss of $9,937 (EPS -$0.25) in Q3 2024. Operating expenses fell sharply to $6,375 from $14,463…
- 10-K · March 26, 2024
- Cognition Therapeutics (CGTX) is a clinical-stage biotech developing CT1812, an oral S2R modulator, currently in multiple Phase 2 programs (SHINE enrolled 158; SHIMMER 120; MAGNIFY up to 246; START planned 540). The…
- 10-Q · August 8, 2023
- Cognition Therapeutics reported improved operating and bottom-line results in Q2: net loss narrowed to $4,726,000 (EPS -$0.16) versus a loss of $5,752,000 (EPS -$0.25) in Q2 2022. Operating expenses declined modestly to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CGTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever